Miflonide Breezhaler

Budesonide, the active ingredient in Miflonide Breezhaler, is an inhaled corticosteroid presented as an inhalation powder for inhalation use. It reduces airway inflammation and is indicated for the long‑term maintenance treatment of asthma and chronic obstructive pulmonary disease in adults, adolescents and children, helping to improve lung function and reduce exacerbations.

GNH USA supplies Miflonide Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance, and reliable distribution.

Budesonide, an inhaled corticosteroid, is used to control airway inflammation in chronic respiratory diseases.

- Asthma: maintenance therapy to control symptoms, reduce frequency of exacerbations and improve lung function. - Chronic obstructive pulmonary disease (COPD): maintenance treatment that helps improve airflow and lowers the risk of disease flare‑ups. - Exercise‑induced bronchospasm in asthma: reduces airway hyper‑responsiveness during physical activity.

Budesonide inhalation may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Oral thrush (candidiasis): fungal infection of the mouth or throat. - Hoarseness or voice change. - Cough or throat irritation after inhalation. - Headache. - Nasal congestion. - Dry mouth. - Nausea.

Serious or Rare Side Effects: - Adrenal suppression leading to fatigue or hypotension. - Pneumonia, especially in patients with COPD. - Paradoxical bronchospasm causing sudden breathing difficulty. - Severe allergic reaction (anaphylaxis) with rash, swelling or difficulty breathing. - Decreased bone mineral density with long‑term high‑dose use.

When using Budesonide inhalation powder, several precautions should be observed to minimize risks and ensure optimal therapy. - Rinse mouth after each use: reduces risk of oral candidiasis. - Use the lowest effective dose: limits systemic exposure. - Monitor for signs of adrenal insufficiency: fatigue, dizziness, low blood pressure. - Avoid abrupt discontinuation: taper under medical supervision to prevent rebound inflammation. - Assess for infections: avoid use during active untreated fungal or bacterial respiratory infections. - Store at room temperature: keep in original packaging, protect from moisture and direct heat.

Budesonide may interact with other medicines, affecting its systemic exposure or therapeutic response.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic budesonide levels and risk of adrenal suppression. - Concomitant use of multiple inhaled corticosteroids: raises risk of systemic side effects. - Live vaccines: systemic corticosteroids can diminish vaccine efficacy.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypokalemia when combined with β2‑agonists. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of gastrointestinal irritation. - Antifungal azoles with moderate CYP3A4 inhibition: may modestly raise budesonide exposure.